By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Roflumilast (topical) (monograph)
Drugs

Roflumilast (topical) (monograph)

https://themeditary.com/drug/roflumilast-topical-monograph-5530.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 12, 2023  Additional Content by TheMediTary.Com

Generic name: zoryve

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Zoryve

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Roflumilast (topical) (monograph)?

Introduction

Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor.

Uses for Roflumilast (Topical)

Plaque Psoriasis

Roflumilast is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Guidelines for the management of psoriasis with topical and alternative agents state that topical agents are most often used for patients with mild to moderate disease; recommendations are not provided for use of roflumilast, which was approved after publication of the guideline.

Roflumilast (Topical) Dosage and Administration

General

Pretreatment Screening

  • Prior to initiating roflumilast, evaluate patients for presence of hepatic dysfunction; roflumilast is contraindicated in patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

Other General Considerations

  • In patients who are breastfeeding, use roflumilast on the smallest area of skin and for the shortest duration possible to minimize potential exposure to the breastfed infant via breast milk. Advise breastfeeding patients not to apply roflumilast directly to the nipple or areola to avoid direct infant exposure.

Administration

Oral Administration

For topical use only. Not for ophthalmic, oral, or intravaginal use. Rub in cream completely until no longer visible on skin. Wash hands after application, unless roflumilast is for treatment of the hands.

Dosage

Pediatric Patients

Plaque Psoriasis
Topical

Pediatric patients ≥12 years of age: Apply once daily to affected areas, including intertriginous areas.

Adults

Plaque Psoriasis
Topical

Apply once daily to affected areas, including intertriginous areas.

Special Populations

Hepatic Impairment

Contraindicated in moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

Renal Impairment

No specific dosage recommendations.

Geriatric Patients

No dosage adjustment necessary; however, greater sensitivity of some older individuals cannot be ruled out.

Detailed Roflumilast topical dosage information

Warnings

Contraindications

  • Moderate to severe liver impairment (Child-Pugh B or C).

Warnings/Precautions

Specific Populations

Pregnancy

No adequate human data available on roflumilast use in pregnancy. In animal studies, oral roflumilast administered during the period of organogenesis produced no fetal structural abnormalities at doses up to 9 and 8 times the maximum recommended human dose. Do not use roflumilast during labor and delivery; animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.

Lactation

No data regarding the presence of roflumilast in human milk, the effects on the breastfed infant, or the effects on milk production.

Excreted into milk of lactating rats and therefore, likely to be present in human milk. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for roflumilast and any potential adverse effects on the breastfed infant or from the underlying maternal condition.

To minimize potential exposure to the breastfed infant via breast milk, use on the smallest area of skin and for the shortest duration possible while breastfeeding. To avoid direct infant exposure, advise breastfeeding patients not to apply roflumilast directly to the nipple and areola.

Pediatric Use

Safety and effectiveness established in pediatric patients ages 12 years and older for the treatment of plaque psoriasis.

Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

Geriatric Use

In clinical trials, 106 subjects with psoriasis exposed to roflumilast or vehicle were 65 years of age or older. No overall differences in safety or effectiveness observed between older subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

Hepatic Impairment

The AUC and Cmax values of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment when roflumilast was orally administered. Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C).

Renal Impairment

Topical roflumilast has not been evaluated in patients with renal impairment. No clinically significant differences in the pharmacokinetics of roflumilast or its roflumilast N-oxide metabolite observed in patients with severe renal impairment following oral administration.

Common Adverse Effects

Adverse effects reported in ≥1% of patients with plaque psoriasis in clinical studies and with an incidence exceeding that of vehicle include diarrhea, headache, insomnia, application site pain, upper respiratory tract infections, and urinary tract infections.

How should I use Roflumilast (topical) (monograph)

General

Pretreatment Screening

  • Prior to initiating roflumilast, evaluate patients for presence of hepatic dysfunction; roflumilast is contraindicated in patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

Other General Considerations

  • In patients who are breastfeeding, use roflumilast on the smallest area of skin and for the shortest duration possible to minimize potential exposure to the breastfed infant via breast milk. Advise breastfeeding patients not to apply roflumilast directly to the nipple or areola to avoid direct infant exposure.

Administration

Oral Administration

For topical use only. Not for ophthalmic, oral, or intravaginal use. Rub in cream completely until no longer visible on skin. Wash hands after application, unless roflumilast is for treatment of the hands.

Dosage

Pediatric Patients

Plaque Psoriasis
Topical

Pediatric patients ≥12 years of age: Apply once daily to affected areas, including intertriginous areas.

Adults

Plaque Psoriasis
Topical

Apply once daily to affected areas, including intertriginous areas.

Special Populations

Hepatic Impairment

Contraindicated in moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment.

Renal Impairment

No specific dosage recommendations.

Geriatric Patients

No dosage adjustment necessary; however, greater sensitivity of some older individuals cannot be ruled out.

Detailed Roflumilast topical dosage information
Roflumilast (topical) (monograph) Dosage information (more detail)

What other drugs will affect Roflumilast (topical) (monograph)?

Extensive metabolism via Phase 1 CYP enzyme and Phase II conjugation reactions. In vitro, metabolized by CYP1A2 and CYP3A4. N-oxide metabolite only major metabolite observed in human plasma. Therapeutic plasma concentrations of roflumilast and its N-oxide metabolite do not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A9/11; therefore, interactions with these enzymes unlikely. In vitro, no induction of CYP1A2, 2A6, 2C9, 2C19, or 3A4/5, and only weak induction of CYP2B6.

No formal drug interaction studies conducted with topical roflumilast.

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP3A4 and CYP1A2: Based on drug interaction studies, the coadministration of roflumilast with systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) may increase roflumilast systemic exposure and can result in increased adverse effects of roflumilast. Weigh the risks of concurrent use of roflumilast against the potential benefits.

Specific Drugs and Foods

Drug

Interaction

Comments

Cimetidine

Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 46% and 85%, respectively; also decreased the Cmax and increased the AUC of roflumilast N-oxide metabolite by 4% and 27%, respectively

Risks of concurrent use should be weighed against benefits.

Enoxacin

Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 20% and 56%, respectively; also decreased the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 14% and 23%, respectively

Risks of concurrent use should be weighed against benefits.

Erythromycin

Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 40% and 70%, respectively; decreased the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 34% and 4%, respectively

Risks of concurrent use should be weighed against benefits.

Fluvoxamine

Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 12% and 156%, respectively; also decreased the roflumilast N-oxide metabolite Cmax by 210% and increased the AUC by 52%

Risks of concurrent use should be weighed against benefits.

Ketoconazole

Coadministration with oral roflumilast increased roflumilast Cmax and AUC by 23% and 99%, respectively, and reduced the Cmax and increased the AUC of the roflumilast N-oxide metabolite by 38% and 3%, respectively

Risks of concurrent use should be weighed against benefits.

Oral contraceptives (containing gestodene and ethinyl estradiol)

Coadministration with oral roflumilast resulted in a 38% increase and 12% decrease in the Cmax of roflumilast and roflumilast N-oxide, respectively Roflumilast and roflumilast N-oxide metabolite AUCs increased by 51% and 14%, respectively

Risks of concurrent use should be weighed against benefits.

More about Roflumilast (topical) (monograph) (Zoryve)

Dosage information
Roflumilast (topical) (monograph) Side Effects
During pregnancy
Zoryve Cream Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Plaque Psoriasis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by